GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » Asset Turnover

Enliven Therapeutics (Enliven Therapeutics) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Enliven Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Enliven Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $307.32 Mil. Therefore, Enliven Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Enliven Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was -32.27%. It is also linked to ROA % through Du Pont Formula. Enliven Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -29.60%.


Enliven Therapeutics Asset Turnover Historical Data

The historical data trend for Enliven Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics Asset Turnover Chart

Enliven Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - -

Enliven Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enliven Therapeutics's Asset Turnover

For the Biotechnology subindustry, Enliven Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enliven Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Enliven Therapeutics's Asset Turnover falls into.



Enliven Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Enliven Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (83.298+271.867)/ 2 )
=0/177.5825
=0.00

Enliven Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (271.867+342.777)/ 2 )
=0/307.322
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Enliven Therapeutics  (NAS:ELVN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Enliven Therapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-90.952/281.809
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-90.952 / 0)*(0 / 307.322)*(307.322/ 281.809)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0905
=ROA %*Equity Multiplier
=-29.60 %*1.0905
=-32.27 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Enliven Therapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-90.952/307.322
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-90.952 / 0)*(0 / 307.322)
=Net Margin %*Asset Turnover
= %*0
=-29.60 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Enliven Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Enliven Therapeutics (Enliven Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Executives
Anish Patel officer: Chief Operating Officer C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Benjamin Hohl officer: Chief Financial Officer 6200 LOOKOUT ROAD, BOULDER CO 80301
Joseph P Lyssikatos director, officer: Chief Scientific Officer 6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz director, officer: President and CEO ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Richard A. Heyman director 5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Rishi Gupta director, 10 percent owner C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Andrew J. Schwab director C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jake Bauer director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vi, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Enliven Therapeutics (Enliven Therapeutics) Headlines